CalciMedica (NASDAQ: CALC) CEO granted new stock warrants

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) reported that its Chief Executive Officer, A. Rachel Leheny, received two warrant grants on August 19, 2026, each for 186,729 warrants to purchase common stock. One warrant has an exercise price of $0.8033 and expires December 25, 2027, with an earlier end date possible 30 days after public disclosure of clearance of the Investigational New Drug Application for CM5480 by the U.S. Food and Drug Administration. The other has an exercise price of $1.00 and expires June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and are subject to a beneficial ownership limitation not to exceed 19.99%. The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, approved by an independent committee of the board.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Leheny A. Rachel

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Warrant F1, F2	186,729	$0.00	$0.00
Grant/Award	Warrant F1, F3	186,729	$0.00	$0.00

Holdings After Transaction: Warrant — 373,458 shares (Direct)

Footnotes (3)

1. F1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
2. F2. The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.
3. F3. The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

Key Figures

First warrant shares: 186,729 warrants Second warrant shares: 186,729 warrants First warrant exercise price: $0.8033 per share +4 more

7 metrics

First warrant shares 186,729 warrants Grant of derivative security to CEO on August 19, 2026 at $0.8033 exercise price

Second warrant shares 186,729 warrants Grant of derivative security to CEO on August 19, 2026 at $1.00 exercise price

First warrant exercise price $0.8033 per share Conversion or exercise price for warrant expiring on the earlier of December 25, 2027 or the CM5480 IND clearance-based date

Second warrant exercise price $1.00 per share Conversion or exercise price for warrant expiring June 25, 2031

First warrant expiration December 25, 2027 Final exercise date unless earlier termination 30 days after CM5480 IND clearance disclosure

Second warrant expiration June 25, 2031 Last date the second warrant may be exercised

Beneficial ownership limitation 19.99% Maximum aggregate beneficial ownership of common stock immediately after warrant exercise

Key Terms

Securities Purchase Agreement, beneficial ownership limitation, Investigational New Drug Application, warrant

4 terms

Securities Purchase Agreement financial

"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

beneficial ownership limitation financial

"would exceed a specified beneficial ownership limitation, not to exceed 19.99%"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Investigational New Drug Application medical

"clearance of its Investigational New Drug Application by the U.S. Food and Drug"

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

warrant financial

"The warrant may be exercised on or after August 19, 2026, and on or prior"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

FAQ

What type of insider transaction did CALC report for CEO A. Rachel Leheny?

CalciMedica, Inc. (CALC) reported that CEO A. Rachel Leheny received two warrant grants on August 19, 2026, each for 186,729 warrants to purchase common stock, as acquisitions coded "A" for grant or award.

How many CalciMedica (CALC) warrants were granted to the CEO and at what exercise prices?

A. Rachel Leheny received two grants of 186,729 warrants each. One warrant has an exercise price of $0.8033 per share, and the other has an exercise price of $1.00 per share, both for underlying CalciMedica common stock.

When can the newly granted CALC warrants to the CEO be exercised and when do they expire?

Both CalciMedica warrants may be exercised on or after August 19, 2026. One expires on the earlier of December 25, 2027 or 30 days after public disclosure of CM5480 IND clearance; the other expires on June 25, 2031.

What is the beneficial ownership limitation on the CALC warrants granted to the CEO?

Each warrant contains a beneficial ownership limitation not to exceed 19.99%. They may not be exercised if the aggregate number of CalciMedica common shares beneficially owned immediately after exercise would exceed that specified limit.

Under what agreement were the CALC warrants issued to the CEO?

The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The agreement and issuance were approved by an independent committee of CalciMedica’s board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 06:36 PM Accepted by SEC EDGAR 08/21/2026 - 06:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leheny A. Rachel

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	$0.8033	08/19/2026		A(1)		186,729		08/19/2026(2)	12/25/2027(2)	Common Stock	186,729	$0	186,729	D
Warrant	$1	08/19/2026		A(1)		186,729		08/19/2026(3)	06/25/2031(3)	Common Stock	186,729	$0	186,729	D

Explanation of Responses:

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

2. The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

3. The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

	/s/ John Dunn, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)